{"doi":"10.1248/bpb.b23-00189","title":"Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome <i>P450 2C9*3</i> Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database","abstract":null,"journal":"Biological and Pharmaceutical Bulletin","year":2023,"id":638832,"datarank":0.38474240361923057,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.0,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1659517,"name":"Katsuhiro Ohyama","orcid":null,"position":1,"is_corresponding":false},{"id":1659518,"name":"Yoichi Tanaka","orcid":null,"position":2,"is_corresponding":false},{"id":1659519,"name":"Hina Nakano","orcid":null,"position":3,"is_corresponding":false},{"id":1659520,"name":"Tasuku Sato","orcid":null,"position":4,"is_corresponding":false},{"id":962992,"name":"Norie Murayama","orcid":null,"position":5,"is_corresponding":false},{"id":1659521,"name":"Makiko Shimizu","orcid":null,"position":6,"is_corresponding":false},{"id":942275,"name":"Yoshiro Saito","orcid":"0000-0002-0559-5889","position":7,"is_corresponding":false},{"id":962538,"name":"Hiroshi Yamazaki","orcid":"0000-0002-1068-4261","position":8,"is_corresponding":false},{"id":1659516,"name":"Koichiro Adachi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome <i>P450 2C9*3</i> Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database","abstract":"The impacts of polymorphic cytochrome P450 (P450 or CYP) 2C9 on drug interactions and the pharmacokinetics of cyclooxygenase inhibitors have attracted considerable attention. In this survey, the prescribed dosage was reduced or discontinued in 150 and 56 patients, respectively, receiving celecoxib and diclofenac prescribed alone, as recorded in a Japanese database of adverse drug events. Among the factors underlying adverse events, intrinsic drug clearance rates may be a contributing factor. The pharmacokinetically modeled plasma concentrations of celecoxib after an oral 200-mg dose increased in CYP2C9*3 homozygotes: the area under the plasma concentration curve was 4.7-fold higher than that in CYP2C9*1 homozygotes. In patients with CYP2C9*3/*3, the virtual hepatic concentrations of diclofenac after three daily 25-mg doses for a week were 11-fold higher than the plasma concentrations in subjects with CYP2C9*1/*1. The in vivo and in vitro fractions of the victim drug metabolized by a specific polymorphic P450 form is an important determining factor for estimating drug-drug interactions. Virtual hepatic and plasma exposures estimated by pharmacokinetic modeling in patients harboring the impaired CYP2C9*3 allele could represent a causal factor for adverse events induced by celecoxib or diclofenac in a manner similar to that for drug interactions.","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37062721","pmcid":null,"openalex_id":"https://openalex.org/W4366080327","authors":[],"funders":[],"total_grants":0,"fwci":2.4667,"citation_percentile":0.87622576,"influential_citations":0,"citation_trend":[{"year":2023,"count":2},{"year":2024,"count":3},{"year":2025,"count":6}],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://www.jstage.jst.go.jp/article/bpb/advpub/0/advpub_b23-00189/_pdf","host_type":"journal"},{"url":"https://www.jstage.jst.go.jp/article/bpb/advpub/0/advpub_b23-00189/_pdf","host_type":"publisher"},{"url":"https://www.jstage.jst.go.jp/article/bpb/46/6/46_b23-00189/_pdf","host_type":"publisher"},{"url":"https://doi.org/10.1248/bpb.b23-00189","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37062721","host_type":"repository"}],"fields_of_study":["Pharmacogenetics and Drug Metabolism","Inflammatory mediators and NSAID effects","Drug Transport and Resistance Mechanisms"],"mesh_terms":["Celecoxib","Administration, Oral","Cytochrome P-450 Enzyme System","Diclofenac","Humans","Japan","Drug-Related Side Effects and Adverse Reactions","Cytochrome P-450 CYP2C9"],"keywords":["Diclofenac","Celecoxib","Medicine","Cytochrome P450","Pharmacology","Pharmacokinetics","Internal medicine","Oral administration","Endocrinology","Metabolism","Pharmacokinetic Modeling","Fraction Metabolized","Cyp2c9.1","Cyp2c9.3"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T21:41:08.168447Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}